Advanced magnetic resonance imaging metrics: Implications for multiple sclerosis clinical trials

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 31, Issue 1, 2009, Pages 29-40

  Zivadinov, Robert ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Disease modifying therapies; Glatiramer acetate; Interferon beta; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; IRON OXIDE; METHYLPREDNISOLONE; IMMUNOLOGIC FACTOR;

BRAIN FUNCTION; BRAIN TISSUE; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DISEASE ACTIVITY; DISEASE COURSE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MACROMOLECULE; MICROSCOPY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; REVIEW; BRAIN; CLINICAL TRIAL; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

BRAIN; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 67649210706     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2009.31.1.1346612     Document Type: Review

References (129)

1. Zivadinov, R., Leist, T.P. Clinical-magnetic resonance imaging correlations in multiple sclerosis. J Neuroimaging 2005, 7(15, Suppl. 4): 10S-21S.
2. Kappos, L., Moeri, D., Radue, E.W. et al.; for the Gadolinium MRI Meta-analysis Group. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: A meta-analysis. Lancet 1999, 353(9157): 964-969
3. McDonald, W.I., Compston, A., Edan, G. et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50(1): 121-127
4. Simon, J.H., Li, D., Traboulsee, A. et al. Standardized MR imaging protocol for multiple sclerosis: Consortium of MS centers consensus guidelines. AJNR Am J Neuroradiol 2006, 27(2): 455-461
5. Polman, C.H., Reingold, S.C., Edan, G. et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005, 58(6): 840-846
6. Thompson, A.J., Miller, D., Youl, B. et al. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 1992, 42(1): 60-63
7. Markovic-Plese, S., McFarland, H.F. Immunopathogenesis of the multiple sclerosis lesion. Curr Neurol Neurosci Rep 2001, 1(3): 257-262
8. van Walderveen, M.A., Kamphorst, W., Scheltens, P. et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998, 50(5): 1282-1288
9. 1-weighted) spin-echo images. Neurology 1995, 45(9): 1684-1690
10. van Waesberghe, J.H.T.M., van Walderveen, M.A.A., Castelijns, J.A. et al. Patterns of lesion development in multiple sclerosis: Longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol 1998, 19(4): 675-683
11. Zivadinov, R., Bakshi, R. Role of MRI in multiple sclerosis II: Brain and spinal cord atrophy. Front Biosci 2004, 9: 647-664
12. Simon, J.H., Jacobs, L.D., Campion, M.K. et al.; and the Multiple Sclerosis Collaborative Research Group (MSCRG). A longitudinal study of brain atrophy in relapsing multiple sclerosis. Neurology 1999 53(1): 139-148
13. Barkhof, F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002, 15(3): 239-245
14. Bakshi, R. Magnetic resonance imaging advances in multiple sclerosis. J Neuroimaging 2005, 15(4, Suppl.): 5S-9S.
15. Rovaris, M., Comi, G., Filippi, M. The role of non-conventional MR techniques to study multiple sclerosis patients. J Neurol Sci 2001, 186(Suppl. 1): S3-S9.
16. Zivadinov, R. Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis? Neurology 2007, 68(22, Suppl. 3): S72-S82.
17. Narayana, P.A. Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging 2005, 15(4, Suppl.): 46S-57S.
18. De Stefano, N., Bartolozzi, M.L., Guidi, L., Stromillo M.L., Federico, A. Magnetic resonance spectroscopy as a measure of brain damage in multiple sclerosis. J Neurol Sci 2005, 233(1-2): 203-208
19. Wolinsky, J.S., Narayana, P.A. Magnetic resonance spectroscopy in multiple sclerosis: Window into the diseased brain. Curr Opin Neurol 2002, 15(3): 247-251
20. Arnold, D.L., Wolinsky, J.S., Matthews, P.M., Falini, A. The use of magnetic resonance imaging spectroscopy in the evaluation of the natural history of multiple sclerosis. J Neurol Neurosurg Psychiatry 1998, 94(Suppl. 1): S94-S101.
21. De Stefano, N., Filippi, M., Miller, D. et al. Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. Neurology 2007, 69(20): 1942-1952
22. De Stefano, N., Matthews, P.M., Antel, J.P., Preul, M., Francis, G., Arnold, D.L. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995, 38(6): 901-909
23. Tourbah, A., Stievenart, J.L., Gout, O. et al. Localized proton magnetic resonance spectroscopy in relapsing remitting versus secondary progressive multiple sclerosis. Neurology 1999, 53(5): 1091-1097
24. Lee, M.A., Blamire, A.M., Pendlebury, S. et al. Axonal injury or loss in the internal capsule and motor impairment in multiple sclerosis. Arch Neurol 2000, 57(1): 65-70.
25. De Stefano, N., Narayanan, S., Francis, G.S. et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001, 58(1): 65-70.
26. De Stefano, N., Matthews, P.M., Fu, L. et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis: Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998, 121(Pt. 8): 1469-1477
27. Brand, A., Richter-Landsberg, C., Leibfritz, D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 1993, 15(3-5): 289-298
28. Chard, D.T., Griffin, C.M., McLean, M.A. et al. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing- remitting multiple sclerosis. Brain 2002, 125(Pt. 10): 2342-2352
29. Narayanan, S., Caramanos, Z., Arnold, D. The effect of glatiramer acetate on axonal integrity in multiple sclerosis. Mult Scler 2004, 10(Suppl. 2): S256.
30. Khan, O., Shen, Y., Caon, C. et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 2005, 11(6): 646-651
31. Sarchielli, P., Presciutti, O., Tarducci, R. et al. 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: Results of a preliminary study. J Neurol Neurosurg Psychiatry 1998, 64(2): 204-212
32. Narayanan, S., De Stefano, N., Francis, G.S. et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 2001, 248(11): 979-986
33. Parry, A., Corkill, R., Blamire, A.M. et al. Beta-interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. J Neurol 2003, 250(2): 171-178
34. Pascual-Lozano, A., Martinez-Bisbal, M.C., Bosca, I. et al. Axonal damage and inflammation in early multiple sclerosis: Effects of subcutaneously interferon-beta-1a treatment. Mult Scler 2006, 12(Suppl. 1): S186.
35. Sajja, B.R., Narayana, P.A., Wolinsky, J.S., Ahn, C.W.; and the PROMiSe Trial MRSI Group. Longitudinal magnetic resonance spectroscopic imaging of primary multiple sclerosis patients treated with glatiramer acetate: Multicenter study. Mult Scler 2008, 14(1): 73-80.
36. Arnold, D.L., Narayanan, S., Antel, S.; for the PreCISe MRS Ancillary Study Group. Treatment with glatiramer acetate protects axons in patients with clinically isolated syndromes: Evidence from the PreCISe trial. Mult Scler 2008, 14: S10.
37. Yong, V.W. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 2002, 59(6): 802-808
38. Schubert, F., Seifert, F., Elster, C. et al. Serial 1H-MRS in relapsing-remitting multiple sclerosis: Effects of interferon-beta therapy on absolute metabolite concentrations. MAGMA 2002, 14(3): 213-222
39. Toprak, M.K., Cakir, B., Ulu, E.M. et al. The effects of interferon beta-1a on proton MR spectroscopic imaging in patients with multiple sclerosis, a controlled study, preliminary results. Int J Neurosci 2008, 118(12): 1645-1658
40. Fernando, K.T.M., McLean, M.A., Chard, D.T. et al. Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain 2004, 127(6): 1361-1369
41. Wattjes, M.P., Harzheim, M., Lutterbey, G.G., Klotz, L., Schild, H.H., Traber, F. Axonal damage but no increased glial cell activity in the normal- appearing white matter of patients with clinically isolated syndromes suggestive of multiple sclerosis using high-field magnetic resonance spectroscopy. AJNR Am J Neuroradiol 2007, 28(8): 1517-1522
42. Wattjes, M.P., Harzheim, M., Lutterbey, G.G. et al. Prognostic value of high-field proton magnetic resonance spectroscopy in patients presenting with clinically isolated syndromes suggestive of multiple sclerosis. Neuroradiology 2008, 50(2): 123-129
43. Fernando, K.T.M., Chard, D.T., McLean, M.A. et al. Metabolite changes in the white matter 3 years after a clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2006, 12: S41.
44. Pelidou, S.H., Giannopoulos, S., Tzavidi, S., Lagos, G., Kyritsis, A.P. Multiple sclerosis presented as clinically isolated syndrome: The need for early diagnosis and treatment. Ther Clin Risk Manag 2008, 4(3): 627-630
45. Horsfield, M.A. Magnetization transfer imaging in multiple sclerosis. J Neuroimaging 2005, 15(4, Suppl.): 58S-67S.
46. Filippi, M., Rocca, M.A. Magnetization transfer magnetic resonance imaging in the assessment of neurological diseases. J Neuroimaging 2004, 14(4): 303-313
47. Filippi, M., Rocca, M.A. Magnetization transfer magnetic resonance imaging of the brain, spinal cord, and optic nerve. Neurotherapeutics 2007, 4(3): 401-413
48. van Waesberghe, J.H.T.M., Kamphorst, W., De Groot, J.A. et al. Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999, 46(5): 747-754
49. Rovaris, M., Agosta, F., Sormani, M.P. et al. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: A medium- term follow-up study. Brain 2003, 126(Pt. 10): 2323-2332
50. Agosta, F., Rovaris, M., Pagani, E., Sormani, M.P., Comi, G. Filippi, M. Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain 2006, 129(Pt. 10): 2620-2627
51. Filippi, M., Rocca, M.A., Pagani, E. et al. European study on intravenous immunoglobulin in multiple sclerosis: Results of magnetization transfer magnetic resonance imaging analysis. Arch Neurol 2004, 61(9): 1409-1412
52. Zivadinov, R., Hussein, N., Abdelrahman, N. et al. Effect of glatiramer acetate on diffusion imaging in patients with multiple sclerosis. Mult Scler 2006, 12(Suppl. 1): S99.
53. Mackenzie, M., Latif, Z., Caon, C., Khan, O. Whole-brain magnetisation transfer imaging changes in relapsing-remitting multiple sclerosis receiving interferon-beta and glatiramer acetate. Mult Scler 2006, 12(Suppl. 1): S171.
54. Richert, N., Bagnato, F., Howard, T. et al. Whole brain magnetization transfer analysis of relapsing-remitting multiple sclerosis patients treated with IFNbeta-1b or glatiramer acetate. Mult Scler 2003, 9(Suppl. 1): S64.
55. Khan, O., Mackenzie, M., Shen, Y., Zak, I., Latif, Z., Caon, C. Combined brain MTR and H-MRS multi-modality approach to investigate mechanism of action of interferon beta and glatiramer acetate in RRMS. Neurology 2007, 68(Suppl. 1): A57.
56. Richert, N.D., Ostuni, J.L., Bash, C.N., Duyn, J.H., McFarland, H.F., Frank, J.A. Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta-1b. AJNR Am J Neuroradiol 1998, 19(9): 1705-1713
57. Kita, M., Goodkin, D.E., Bacchetti, P., Waubant, E., Nelson, S.J., Majumdar, S. Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a. Neurology 2000, 54(9): 1741-1745
58. Richert, N.D., Ostuni, J.L., Bash, C.N., Leist, T.P., McFarland, H.F., Frank, J.A. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. Mult Scler 2001, 7(1): 49-58.
59. Inglese, M., van Waesberghe, J.H.T.M., Rovaris, M. et al. The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS. Neurology 2003, 60(5): 853-860
60. Chen, J.T., Collins, D.L., Atkins, H.L. et al.; Canadian MS/BMT Study Group. Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol 2008, 63(2): 254-262
61. Fernando, K.T.M., Tozer, D.J., Miszkiel, K.A. et al. Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis. Brain 2005, 128(Pt. 12): 2911-2925
62. Rovaris, M., Gass, A., Bammer, S. et al. Diffusion MRI in multiple sclerosis. Neurology 2005, 65(10): 1526-1532
63. Pagani, E., Bammer, R., Horsfield, M.A. et al. Diffusion MR imaging in multiple sclerosis: Technical aspects and challenges. AJNR Am J Neuroradiol 2007, 28(3): 411-420
64. Goldberg-Zimring, D., Mewes, A.U.J., Maddah, M., Warfield, S.K. Diffusion tensor magnetic resonance imaging in multiple sclerosis. J Neuroimaging 2005, 15(4, Suppl.): 68S-81S.
65. Gallo, A., Rovaris, M., Riva, R. et al. Diffusion-tensor magnetic resonance imaging detects normal-appearing white matter damage unrelated to short-term disease activity in patients at the earliest clinical stage of multiple sclerosis. Arch Neurol 2005, 62(5): 803-808
66. Guo, A.C., Jewells, V.L., Provenzale, J.M. Analysis of normal-appearing white matter in multiple sclerosis: Comparison of diffusion tenor MR imaging and magnetization transfer imaging. AJNR Am J Neuroradiol 2001, 22(10): 1893-1900
67. Cercignani, M., Inglese, M., Pagani, E., Comi, G., Filippi, M. Mean diffusivity and fractional anisotropy histograms of patients with multiple sclerosis. AJNR Am J Neuroradiol 2001, 22(5): 952-958
68. Erskine, M.K., Cook, L.L., Riddle, K.E., Mitchell, J.R., Karlik, S.J. Resolution-dependent estimates of multiple sclerosis lesion loads. Can J Neurol Sci 2005, 32(2): 205-212
69. Sicotte, N.L., Voskuhl, R.R., Bouvier, S., Klutch, R., Cohen, M.S., Mazziotta, J.C. Comparison of multiple sclerosis lesions at 1.5 and 3.0 Tesla. Invest Radiol 2003, 38(7): 423-427
70. Wattjes, M.P., Harzheim, M., Kuhl, C.K. et al. Does high-field MR imaging have an influence on the classification of patients with clinically isolated syndromes according to current diagnostic MR imaging criteria for multiple sclerosis? AJNR Am J Neuroradiol 2006, 27(8): 1794-1798
71. Wolansky, L.J., Cook, S.D., Sheynzon, V. et al. Betaseron® vs. Copaxone® in multiple sclerosis with triple-dose gadolinium and 3-T MRI endpoints (BECOME): Efficacy of the optimised MRI protocol and announcement of primary study outcome. Mult Scler 2006, 12(Suppl. 1): S98.
72. Lincoln, J., Belenguer, A., Vidgop, E. et al. Comparison of Betaseron® and Copaxone® on newly enhancing lesions by monthly 3T MRI with triple dose gadolinium: Secondary outcomes in a 15-month analysis of the BECOME study. Neurology 2007, 68(Suppl. 1): A331.
73. Wolansky, L., Cook, S., Skurnick, J. et al. Betaseron vs Copaxone in MS with triple-dose gadolinium and 3-T MRI endpoints (BECOME): Announcement of final primary study outcome. 23rd Congr Eur Comm Treat Res Multiple Scler (ECTRIMS) (Oct 11-14, Prague) 2007, Abst 206.
74. Kraus, J., Oschmann, P. The impact of interferon-beta treatment on the blood-brain barrier. Drug Discov Today 2006, 11(15-16): 755-762
75. Buckle, G.J. Functional magnetic resonance imaging and multiple sclerosis: The evidence for neuronal plasticity. J Neuroimaging 2005, 15(4, Suppl.): 82S-93S.
76. Parry, A.M.M., Scott, R.B., Palace, J., Smith, S., Matthews, P.M. Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. Brain 2003, 126 (Pt. 12): 2750-2760
77. Reddy, H., Narayanan, S., Matthews, P.M. et al. Relating axonal injury to functional recovery in MS. Neurology 2000, 54(1): 236-239
78. Clanet, M., Berry, I. Magnetic resonance imaging in multiple sclerosis. Curr Opin Neurol 1998, 11(4): 299-303.
79. Pantano, P., Mainero, C., Caramia, F. Functional brain reorganization in multiple sclerosis: Evidence from fMRI studies. J Neuroimaging 2006, 16(2): 104-114
80. Rocca, M.A., Agosta, F., Colombo, B. et al. fMRI changes in relapsingremitting multiple sclerosis patients complaining of fatigue after IFNbeta- 1A injection. Human Brain Mapp 2007, 28(5): 373-382
81. Bakshi, R., Ariyaratana, S., Benedict, R.H.B., Jacobs, L. Fluid-attenuated inversion recovery magnetic resonance imaging detects cortical and juxtacortical multiple sclerosis lesions. Arch Neurol 2001, 58(5): 742-748
82. Mills, R.J., Young, C.A., Smith, E.T.S. 3D MRI in multiple sclerosis: A study of three sequences at 3T. Br J Radiol 2007, 80(953): 307-320
83. Bink, A., Schmitt, M., Gaa, J., Muggler, J.P. 3rd, Lanfermann, H., Zanella, F.E. Detection of lesions in multiple sclerosis by 2D FLAIR and single-slab 3D FLAIR sequences at 3.0 T: Initial results. Eur Radiol 2006, 16(5): 1104-1110
84. Geurts, J.J.G., Pouwels, P.J.W., Uitdehaag, B.M.J., Polman, C.H., Barkhof, F., Castelijns, J.A. Intracortical lesions in multiple sclerosis: Improved detection with 3D double inversion-recovery MR imaging. Radiology 2005, 236(1): 254-260
85. Mugler J.P. 3rd., Bao, S., Mulkern, R.V. et al. Optimized single-slab three-dimensional spin-echo MR imaging of the brain. Radiology 2000, 216(3): 891-899
86. Moraal, B., Roosendaal, S.D., Pouwels, P.J.W. et al. Multi-contrast, isotropic, single-slab 3D MR imaging in multiple sclerosis. Eur Radiol 2008, 18(10): 2311-2320
87. Bruck, W., Porada, P., Poser, S. et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995, 38(5): 788-796
88. Dousset, V., Delalande, C., Ballarino, L. et al. In vivo macrophage activity imaging in the central nervous system detected by magnetic resonance. Magn Reson Med 1999, 41(2): 329-333
89. Dousset, V., Ballarino, L., Delalande, C. et al. Comparison of ultrasmall particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2- weighted, and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmune encephalomyelitis. AJNR Am J Neuroradiol 1999, 20(2): 223-227
90. Rausch, M., Hiestand, P., Baumann, D., Cannet, C., Rudin, M. MRI-based monitoring of inflammation and tissue damage in acute and chronic relapsing EAE. Magn Reson Med 2003, 50(2): 309-314
91. Dousset, V., Brochet, B., Deloire, M.S.A. et al. MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium. AJNR Am J Neuroradiol 2006, 27(5): 1000-1005
92. Vellinga, M.M., Engberink, R.D.O., Seewann, A. et al. Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. Brain 2008, 131(Pt. 3): 800-807
93. Brochet, B., Deloire, M.S., Touil, T. et al. Early macrophage MRI of inflammatory lesions predicts lesion severity and disease development in relapsing EAE. Neuroimage 2006, 32(1): 266-274
94. Frohman, E.M., Costello, F., Stuve, O. et al. Modeling axonal degeneration within the anterior visual system: Implications for demonstrating neuroprotection in multiple sclerosis. Arch Neurol 2008, 65(1): 26-35.
95. Frohman, E., Costello, F., Zivadinov, R. et al. Optical coherence tomography in multiple sclerosis. Lancet Neurol 2006, 5(10): 853-863
96. McDonald, W.I., Barnes, D. The ocular manifestations of multiple sclerosis I: Abnormalities of the afferent visual system. J Neurol Neurosurg Psychiatry 1992, 55(9): 747-752
97. Frohman, E.M., Frohman, T.C., Zee, D.S., McColl, R., Galetta, S. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 2005, 4(2): 111-121
98. Sergott, R.C. Optical coherence tomography: Measuring in-vivo axonal survival and neuroprotection in multiple sclerosis and optic neuritis. Curr Opin Ophthalmol 2005, 16(6): 346-350
99. Patrikios, P., Stadelmann, C., Kutzelnigg, A. et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006, 129(Pt. 12): 3165-3172
100. Barkhof, F., Bruck, W., De Groot, C.J.A. et al. Remyelinated lesions in multiple sclerosis: Magnetic resonance imaging appearance. Arch Neurol 2003, 60(8): 1073-1081
101. Simon, J.H., Jacobs, L.D., Campion, M. et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Ann Neurol 1998, 43(1): 79-87.
102. Simon, J.H., Lull, J., Jacobs, L.D. et al. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Neurology 2000, 55(2): 185-192
103. Rudick, R.A., Fisher, E., Lee, J.C., Simon, J., Jacobs, L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology 1999, 53(8): 1698-1704
104. Khan, O., Mackenzie, M., Bao, F. et al. Effect of disease-modifying therapies on brain atrophy in early and mildly affected relapsing-remitting multiple sclerosis over a long-term period: Results of a five-year imaging study. 23rd Congr Eur Comm Treat Res Multiple Scler (ECTRIMS) (Oct 11-14, Prague) 2007, Abst.
105. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001, 56(12): 1628-1636
106. Li, D.K., Zhao, G.J., Paty, D.W.; and the University of British Columbia MS/MRI Analysis Research Group. The SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 2001, 56(11): 1505-1513
107. Kappos, L., Traboulsee, A., Constantinescu, C. et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006, 67(6): 944-953
108. Gasperini, C., Paolillo, A., Giugni, E. et al. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta- 1a. Mult Scler 2002, 8(2): 119-123
109. Jones, C.K., Riddehough, A., Li, D.K.B. et al. MRI cerebral atrophy in relapsing-remitting MS: Results from the PRISMS trial. Neurology 2001, 56(Suppl. 3): A379.
110. Li, D.K., Paty, D.W. Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis. Ann Neurol 1999, 46(2): 197-206.
111. Mikol, D.D., Barkhof, F., Chang, P. et al. The REGARD trial: A randomized assessor-blinded trial comparing interferon beta-1a and glatiramer acetate in relapsing-remitting multiple sclerosis. 23rd Congr Eur Comm Treat Res Multiple Scler (ECTRIMS) (Oct 11-14, Prague) 2007, Abst 119.
112. Paty, D.W., Li, D.K. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43(4): 662-667
113. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 1995, 45(7): 1277-1285
114. Double-blind randomized multicenter dose-comparison study of interferon- beta-1a (AVONEX): Rationale, design and baseline data. Mult Scler 2001, 7(3): 179-183
115. Miller, D.H., Molyneux, P.D., Barker, G.J., MacManus, D.G., Moseley, I.F., Wagner, K. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double-blind, placebo-controlled trial. Ann Neurol 1999, 46(6): 850-859
116. Bagnato, F., Gupta, S., Richert, N.D. et al. Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations. Arch Neurol 2005, 62(11): 1684-1688
117. Cadavid, D., Gomez-Choco, M., Alemany, M. et al. Outcome of T1 hypodensities in patients with early forms of multiple sclerosis randomised to Betaseron or Copaxone and followed prospectively by monthly 3T MRI for up to 2 years: Preliminary analysis of the BECOME study. Mult Scler 2006, 12(Suppl. 1): S97.
118. Molyneux, P.D., Kappos, L., Polman, C. et al. The effect of interferon beta- 1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. Brain 2000, 123(Pt. 11): 2256-2263
119. Frank, J.A., Richert, N., Bash, C. et al. Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients. Neurology 2004, 62(5): 719-725
120. Polman, C.H., O'Connor, P.W., Havrdova, E. et al.; and the AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354(9): 899-910.
121. Rudick, R.A., Stuart, W.H., Calabresi, P.A. et al.; and the SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006, 354(9): 911-923
122. Dalton, C.M., Miszkiel, K.A., Barker, G.J. et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 2004, 251(4): 407-413
123. Fisher, E., O'Connor, P.O., Havrdova, E. et al. Natalizumab effect on brain atrophy in RRMS (AFFIRM study). J Neurol 2005, 252(Suppl. 2): 149.
124. O'Connor, P., Goodman, A., Kappos, L. et al. The efficacy of natalizumab monotherapy over 3 years of treatment in patients with relapsing multiple sclerosis. Neurology 2007, 68(Suppl. 2): A275.
125. Cree, B., Ratiney, H., Owen, M., Evangelista, A., Oh, J., Pelletier, D. Magnetic resonance spectroscopy effects of natalizumab: Single center results from the SENTINEL study. Annu Meet Am Acad Neurol (May 1, Boston) 2007, Abst P02.047.
126. Comi, G., Filippi, M., Wolinsky, J.S. European/Canadian multicenter, double- blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001, 49(3): 290-297
127. Filippi, M., Rovaris, M., Rocca, M.A., Sormani, M.P., Wolinsky, J.S., Comi, G.; and the European/Canadian Glatiramer Acetate Study Group. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes." Neurology 2001, 57(4): 731-733
128. Sormani, M.P., Rovaris, M., Valsasina, P., Wolinsky, J.S., Comi, G., Filippi, M. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology 2004, 62(8): 1432-1434
129. Ge, Y., Grossman, R.I., Udupa, J.K. et al. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: Quantitative MR assessment. Neurology 2000, 54(4): 813-817